Welcome to our dedicated page for CNBX Pharms SEC filings (Ticker: CNBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
cannabics pharmaceuticals is dedicated to the development of advanced cannabinoid-based treatments and therapies. the company’s main focus is the development of novel therapies and biotechnological tools aimed to providing relief from diverse ailments and treat human malignancies. these advanced tools include novel delivery systems, personalized medicine diagnostics and therapies based on cannabinoid compounds. cannabics' research is devoted to the discovery of cannabinoid compounds targeted to specific cancers based on cutting edge high through-output screening and bioinformatic tools. the company’s principal product is cannabics sr, a long acting oil capsule that provides a safe, effective and reliable administration of cannabis. composed solely from food grade materials, cannabics sr 25mg delivers a steady level of beneficial effects for 10–12 hours . the once-per day oral dosing regimen offered by cannabics sr allows patients a more consistent therapeutic effect throughout theCNBX Pharmaceuticals Inc. reported a larger quarterly loss and severe liquidity pressure for the three months ended November 30, 2025. The company generated no revenue and posted a net loss of $113,719, compared with $34,352 a year earlier, mainly from higher general and administrative expenses and increased interest on loans.
Cash and cash equivalents fell to $7,703, while current liabilities reached $2,584,133, leaving a stockholders’ deficit of $2,572,971. Management and the auditors highlight “substantial doubt” about the company’s ability to continue as a going concern, noting cumulative losses of $25,382,095 and the need for new financing.
To reduce debt, CNBX converted loans and interest totaling $37,041 into 199,234,460 new shares during the quarter, increasing shares outstanding to 753,196,666 at November 30, 2025. Subsequent conversions through early January 2026 added another 117,571,429 shares for $32,920 of debt, further diluting existing holders. The company also relies on forbearance agreements with an institutional investor on a senior secured note while it seeks additional capital.
CNBX Pharmaceuticals Inc. (CNBX) is a Bethesda‑based, clinical‑stage biotech focused on cannabinoid‑based cancer therapies. The company’s lead candidates are Cannabics SR, an oral sustained‑release capsule for cancer anorexia‑cachexia syndrome (CACS), and RCC‑33, a cannabinoid formulation targeting colorectal cancer. Cannabics SR has shown weight gain and appetite benefits in a small peer‑reviewed pilot study, while RCC‑33 has reduced colorectal tumor volume in preclinical models. CNBX plans, contingent on new financing, to run Phase I/II(a) trials for both drugs starting in 2026 and estimates RCC‑33’s early human proof‑of‑concept program at about $6.5 million. The company has no significant revenue, outsources GMP manufacturing, and intends to monetize its pipeline mainly through partnerships and licensing rather than its own sales force. Its auditors have raised substantial doubt about CNBX’s ability to continue as a going concern, and the business depends heavily on raising additional capital and retaining a very small management team.
CNBX Pharmaceuticals (CNBX): Schedule 13G/A Amendment No. 6 filed by 3i, LP, 3i Management LLC, and Maier Joshua Tarlow reports beneficial ownership of 80,865,244 shares, representing 9.99% of CNBX common stock.
The position includes 24,600,000 shares held and 56,265,244 shares issuable upon conversion of a senior secured convertible note, subject to a 9.99% beneficial ownership limitation (the “Blocker”). CNBX had 753,196,666 shares outstanding as of September 30, 2025.
The reporting persons indicate shared voting and dispositive power over 80,865,244 shares and no sole power. They certify the securities are not held for the purpose of changing or influencing control of the issuer.
FAQ
What is the current stock price of CNBX Pharms (CNBX)?
What is the market cap of CNBX Pharms (CNBX)?
